Remove Gene Remove Gene Editing Remove Genome Remove Life Science
article thumbnail

Gene Editing Innovations with Programmable Gene Insertion (PGI) Technology ft. John Finn, PhD, CSO, Tome Biosciences – Xtalks Life Science Podcast Ep. 160

XTalks

In this episode, Ayesha spoke with John Finn, PhD, Chief Scientific Officer at Tome Biosciences , a company developing programmable gene insertion (PGI) technology. PGI is a cutting-edge gene editing technology that allows for the insertion of large sequences of DNA with site-specific precision.

article thumbnail

Interview with the Jones!Lab on development of novel genome editing tools

Drug Discovery Today

27, Vilnius will host the EFIB’2022 event which will bring the European life science sector together. In the field of life sciences, Lithuania is best known for the discovery of gene scissors by Prof. Lab, focused on research and development of novel genome editing tools. Virginijus Šikšnys.

Genome 85
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Interview with the Jones!Lav on development of novel genome editing tools

Drug Discovery Today

27, Vilnius will host the EFIB’2022 event which will bring the European life science sector together. In the field of life sciences, Lithuania is best known for the discovery of gene scissors by Prof. Lab, focused on research and development of novel genome editing tools. Virginijus Šikšnys.

Genome 40
article thumbnail

Revvity opens Scientific Centre of Excellence for genomics

Drug Discovery World

Chris Hughes, Managing Director North Europe, Revvity, said: “We are thrilled to be part of the UK’s life sciences industry through our Scientific Centre of Excellence and top expertise in Cambridge. The centre also features a newly built demo lab which will bring the Revvity portfolio closer to scientists.

Genome 52
article thumbnail

BioSpace's Inaugural Best Places to Work Report Reveals Industry's Top Choice Employers

BioSpace

This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.

article thumbnail

Exa-Cel CRISPR Gene Therapy for Sickle Cell Disease Deemed Safe by FDA Advisory Panel

XTalks

After spending almost an entire day deliberating the safety of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ CRISPR-based gene therapy exa-cel for sickle cell disease, a US Food and Drug Administration (FDA) advisory panel appears to be satisfied with what it saw. CRISPR works as genetic scissors to edit parts of the genome.

article thumbnail

Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug

XTalks

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52